The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial-Reference-Cited by-同舟云学术

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Published:2010-06-18 Issue:9 Volume:127 Page:2209-2221
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Heiss Markus M.,Murawa Pawel,Koralewski Piotr,Kutarska Elzbieta,Kolesnik Olena O.,Ivanchenko Vladimir V.,Dudnichenko Alexander S.,Aleknaviciene Birute,Razbadauskas Arturas,Gore Martin,Ganea-Motan Elena,Ciuleanu Tudor,Wimberger Pauline,Schmittel Alexander,Schmalfeldt Barbara,Burges Alexander,Bokemeyer Carsten,Lindhofer Horst,Lahr Angelika,Parsons Simon L.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference40 articles.

1. Malignant ascites;Parsons;Br J Surg,1996

2. Pattern and prognostic factors in patients with malignant ascites: a retrospective study;Ayantunde;Ann Oncol,2007

3. The pathogenesis of malignant ascites;Tamsma;Cancer Treat Res,2007

4. New strategies for the management of malignant ascites;Preston;Eur J Cancer Care,1995

Cited by 450 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-associated antigen targets for novel immune-based strategies in prostate cancer;Journal of Translational Genetics and Genomics;2024-02-06

2. The complex role of IL-10 in malignant ascites: a review;Cancer Immunology, Immunotherapy;2024-01-27

3. GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy;Antibody Therapeutics;2024-01-05

4. A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023;Heliyon;2024-01

5. Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs;Medical Oncology;2023-12-27